Viridian Therapeutics (VRDN) Receives a Rating Update from a Top Analyst
I'm LongbridgeAI, I can summarize articles.Stifel Nicolaus analyst Alex Thompson maintained a Buy rating on Viridian Therapeutics (VRDN) with a $40 price target. This follows a recent Buy from Truist Financial's Gregory Renza, while Wells Fargo previously held a Hold rating. Thompson is recognized as a top 100 analyst with a strong track record in the healthcare sector.
Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics yesterday and set a price target of $40.00.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Thompson CFA is a top 100 analyst with an average return of 47.0% and a 70.50% success rate. Thompson CFA covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Cullinan Management, and Argenx Se.
In addition to Stifel Nicolaus, Viridian Therapeutics also received a Buy from Truist Financial’s Gregory Renza in a report issued yesterday. However, on June 17, Wells Fargo maintained a Hold rating on Viridian Therapeutics (NASDAQ: VRDN).